Stock Market Today, March: CytomX Surges on Positive Data
CytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
Learn what index values indicate and how to use them to gauge market direction, volatility, and relative strength in your analysis.
8,600 articlesCytomX Therapeutics delivered a sharp rally after promising Phase 1 data for its colorectal cancer program. This arti...
As housing markets shift, investors wonder if Opendoor can deliver a meaningful stock reaction by 2026. This guide br...
As earnings season unfolds, Innventure (INV) investors want clarity on growth, margins, and guidance. This article br...
For the 16th straight week, home listing prices fall across many markets as higher borrowing costs and rising invento...
Dave & Buster's is blending food, drinks, and arcade play into a growing business model. This analysis breaks down th...
Bank of America finished the Fed stress tests without a dividend hike while peers boosted payouts. Here’s what the ba...
Palantir faces a pivotal investor update that could move the stock. This guide breaks down the risks, catalysts, and ...
Xenon stock sits at $42 as insiders trim significant positions ahead of a pivotal March Phase 3 readout. This guide b...
A thorough, original take on Eastern (EML) 2025 earnings, spotlighting Q4 results, margin trends, and guidance. Learn...
Nebius stock fell today after the company announced debt issuance to fund its infrastructure push and key AI partners...
California luxury builder Thomas James Homes announces a new growth plan under CEO Steve Schlageter, centering on pre...
A niche tech stock tied to crypto and forecasting markets surged today, driven by fresh funding and upbeat sentiment ...